The FDA granted accelerated approval to Replimune’s Tudriqev with nivolumab on August 6, 2026, for advanced melanoma after anti-PD-1 therapy. The decision is significant because FDA had previously rejected the application twice over efficacy concerns. For Regulatory Affairs and clinical
